Browsing by Author "Harysh, Winster"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    FABATIN-LOADED SILICA NANOPARTICLE-INDUCED APOPTOSIS VIA MITOCHONDRIAL DYSFUNCTION: TARGETING THE PI3K/AKT MOLECULAR PATHWAY AS A THERAPEUTIC IMPLICATION AGAINST TRIPLE NEGATIVE BREAST CANCER
    (The Royal Society of Chemistry, 2021) Sennimalai, Ramya; Manickam, Paulpandi; Krishnamoorthy, Kavithaa; Thiruvenkataswamy, Saranya; Harysh, Winster; Vellingiri, Balachandar; Arul, Narayanasamy
    Although chemotherapeutics plays a pivotal role in the therapy of many aggressive cancers, there are many pitfalls including multidrug resistance and lack of selectivity which result in progression of the cancer. Triple negative breast cancer (TNBC) is one such aggressive type of breast cancer with minimal therapeutic approaches. As TNBC is associated with high risk of metastasis and low survival percentage, an immense requisite to expand the therapeutic strategy is needed. In support of this quest, an attempt was made to exploit the anticancer efficacy of fabatin, a phytodefensin peptide obtained from the seeds of Vicia faba, along with the biocompatible nanocarrier silica as a therapeutic strategy against TNBC. The current work was intended to isolate the plant defensin cationic antimicrobial peptide fabatin from the seeds of Vicia faba and also to load it in mesoporous silica nanoparticles (F-SNP) to increase its efficiency in the TNBC system, both in vitro using MDA-MB-231 cells and in vivo in a xenograft mice model. In vitro studies demonstrated the efficient role of F-SNP against MDA-MB-231 cells with inhibitory concentration (IC50) of 7.8 ± 0.9 μg mL−1 while showing least significant effect on normal breast MCF-10A cells. The appearance of apoptotic bodies specifies the cell death promoted by isolated cationic defensin peptide fabatin. Moreover, expression studies evinced the downregulation of PI3K which further resulted in the upregulation of pro-apoptotic proteins and downregulation of anti-apoptotic proteins. Further in vivo studies supported our in vitro findings by confirming a significant reduction in tumor volume. Histopathological observations confirm the absence of noteworthy effect in F-SNP treated mice model. Our findings altogether indicated F-SNP to be a most promising drug with significant pharmaceutical potential in the treatment of TNBC cells.
  • No Thumbnail Available
    Item
    PH DEPENDENT DRUG RELEASE OF SILIBININ, A POLYPHENOL CONJUGATED WITH MAGNETIC NANOPARTICLE AGAINST THE HUMAN COLON CANCER CELL
    (SpringerLink, 2020-04-03) Sennimalai, Ramya; Saranya, Thiruvenkataswamy; Krishnamoorthy, Kavithaa; Sivashanmugam, Preethi; Harysh, Winster; Vellingiri, Balachander; Manickam, Paulpandi; Arul, Narayanasamy
    Magnetic nanocarriers has become popularised in the research field as well as in the biomedical application due to their unique exotic possession, and processability. The present study involves the synthesis of nanocarrier, Iron Oxide nanoparticle conjugated with silibinin (SLN-Fe2O3) using co-precipitation method and also to detect their efficacy against the colon cancer cell. The synthesized SLN-Fe2O3 were undertaken for several analysis including UV-visible spectroscopy, dynamic light scattering, scanning electron microscope, Fourier transform infra-red spectroscopy, zeta potential analysis, and X-ray diffraction analysis. The analysis had end up in confirming the polydispersity and crystalline nature of the synthesized SLN-Fe2O3 with an average size of 70 nm. Further the synthesized SLN-Fe2O3 was undertaken for in vitro (AO/EtBR and DAPI) studies to find their effectiveness against human colon cancer using HT-29 cell line. The fragmentation occurs in nuclear material of the SLN-Fe2O3 treated cells had revealed that the cell death was due to the induction of apoptotic signals in the treated cancer cells. Thus the current study had clearly validated the potency of synthesized Iron Oxide nanoparticles conjugated with silibinin (SLN-Fe2O3) against the colon cancer cell and holds a promising therapeutic potency in treating cancer cells.